Thera-SAbDab

DURVALUMAB

>   Structural Summary
TherapeuticDurvalumab
TargetCD274
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS
Light ChainEIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK
100% seqID Fv Structure5xj4%3AHL%2F5x8m%3ABC [Fvs: ]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (August '23)Approved
Estimated Status (August '23)Active
Recorded Developmental TechnologyAbgenix XenoMouse
INN Year Proposed2014
INN Year Recommended2015
Companies InvolvedAdvaxis%3BAIO Studien gGmbH%3BAstraZeneca%3BBig Ten Cancer Research Consortium%3BCanadian Cancer Trials Group%3BCase Comprehensive Cancer Center%3BCelgene International SARL%3BCentre hospitalier de l%27Universite de Montreal%3BCentre Leon Berard%3BCharite - Universitatsmedizin Berlin%3BChildrens Hospital Los Angeles%3BDana-Farber Cancer Institute%3BEli Lilly%3BFondazione IRCCS Istituto Nazionale dei Tumori%3BGlaxoSmithKline%3BGradalis%3BGrand Hopital de Charleroi%3BGrupo Espanol de Tumores Neuroendocrinos%3BGustave Roussy%3BImmunocore%3BInnate Pharma%3BInstitut Claudius Regaud%3BJuno Therapeutics%3BKyoto Breast Cancer Research Network%3BLudwig Institute for Cancer Research%3BM. D. Anderson Cancer Center%3BMedImmune%3BMemorial Sloan-Kettering Cancer Center%3BMirati Therapeutics%3BMyriad Genetic Laboratories%3BNational Cancer Institute %28USA%29%3BNational Health and Medical Research Council%3BNorthwestern University%3BPharmacyclics%3BPlexxikon%3BRadboud University%3BSamsung Medical Center%3BSpanish Oncology Genito-Urinary Group%3BSwiss Group for Clinical Cancer Research%3BUNC Lineberger Comprehensive Cancer Center%3BUNICANCER%3BUniversity College London%3BUniversity of Colorado at Denver%3BUniversity of Kansas Medical Center%3BUniversity of Maryland Greenbaum Cancer Center%3BUniversity of Southern California%3BUniversity of Sydney%3BUniversity of Texas M. D. Anderson Cancer Center%3BVentiRx Pharmaceuticals%3BWashington University School of Medicine%3BYale University%3BYonsei University College of Medicine
Conditions ApprovedNon-small cell lung cancer%3BUrogenital cancer
Conditions ActiveBiliary cancer%3BBladder cancer%3BCervical cancer%3BFallopian tube cancer%3BHead and neck cancer%3BLiver cancer%3BOvarian cancer%3BPeritoneal cancer%3BRenal cell carcinoma%3BSmall cell lung cancer%3BSolid tumours%3BBreast cancer%3BGynaecological cancer%3BPancreatic cancer%3BAcute myeloid leukaemia%3BBrain metastases%3BCholangiocarcinoma%3BColorectal cancer%3BDiffuse large B cell lymphoma%3BEndometrial cancer%3BGallbladder cancer%3BGastric cancer%3BGerm cell and embryonal neoplasms%3BGlioblastoma%3BMesothelioma%3BMultiple myeloma%3BMyelodysplastic syndromes%3BNeuroendocrine tumours%3BOesophageal cancer%3BOropharyngeal cancer%3BProstate cancer%3BSarcoma%3BSoft tissue sarcoma%3BChronic lymphocytic leukaemia%3BCutaneous T-cell lymphoma%3BHaematological malignancies%3BLung cancer%3BLymphoma%3BMalignant melanoma%3BNon-Hodgkin%27s lymphoma%3BPeripheral T-cell lymphoma%3BRenal cancer%3BCNS cancer%3BGastrointestinal cancer%3BLymphoproliferative disorders%3BMyelofibrosis%3BThyroid cancer%3BVulvovaginal cancer
Conditions Discontinuedna
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy